EN DE
Watch Fluicell AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Fluicell AB (FLUI) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Fluicell AB stock SEK 24.59, price SEK 27.50, that is 10.6% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0010831321

FA Fluicell AB logo Thin data Nov 10, 2026

Fluicell AB

FLUI · ST
Expensive, weak quality

Our calculation puts a fair price 11% below what the stock costs today.

Solidly profitable · 15.2% net margin (TTM)
Ranks above peers (8/11)
Expensive Growth (revenue 5y +5.3 %/yr in SEK)
Moderate moat 55/100 · thin data
Fair value kr 24.59 · Overvalued
Quality 38/100
Negative free cash flow
Thin data
Estimate
Watch Fluicell AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 2,295 kr 7.70 Fair Value kr 24.59 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 7.70 – kr 2,295 · fair‑value band kr 18.44 – kr 30.73 · the kr 27.50 price screens above the kr 24.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Fluicell in your weekly email

Every Wednesday you see whether Fluicell is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden.

Show moreShow less

The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.

It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet.

Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.

Stock analysis

Fluicell AB (FLUI) currently trades at kr 27.50, while our estimate is kr 24.59, 11% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 18.44 (bear) to kr 30.73 (bull), the price of kr 27.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Fluicell AB reported revenue of 6.0M SEK in FY2025 versus 2.6M SEK in FY2021, a compound +23.2%/yr. Reported net income was −8.3M SEK in FY2025.

Key figures

Market cap 37.8M SEK (≈ $3.8M) Micro · P/E ratio 13.5 · P/S ratio 2.05 · EPS (TTM) kr 2.04 · Net margin 15.2% · Return on equity 18.6% · Return on assets (EBIT) −109% (5-year average) · Operating margin 30.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 246% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −11%, FLUI screens richer than that median.

Fair Value

Bear kr 18.44 Fair Value kr 24.59 Bull kr 30.73
Price kr 27.50 · Downside -10.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 58
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+222.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Start year 2020 (pandemic). Over 10 years: +15.5% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−367.3% (2020) → −144.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

FLUI screens overvalued: fair value 11% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Fluicell AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −10.6% · Top 25%
Profitability
Return on equity (12 months) 18.6% · Top 25%
Return on assets −45.1% · Below median
Net margin (12 months) 15.2% · Above median
Operating margin (12 months) 30.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 933.7% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 13.5× · Cheaper than median
P/B 3.47× · Pricier than median
P/S (12 months) 2.05× · Cheapest 25%
EV/EBITDA 12.1× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)19 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)74 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs FLUI
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs FLUI
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs FLUI
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs FLUI
argenx SE ARGX $971.55 $908.40 −7% vs FLUI
CSL Limited CSL A$201.68 A$181.40 −10% vs FLUI
Moderna, Inc MRNA $250.83 $158.70 −37% vs FLUI
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs FLUI
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs FLUI
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs FLUI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Fluicell AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Fluicell AB Fair Value". https://www.fairvalue-calculator.com/stock/FLUI

Frequently asked questions

Is Fluicell AB (FLUI) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 24.59 versus a price of kr 27.50, about 11% lower (overvalued).
What is the fair value of FLUI?
Our estimate for Fluicell AB is kr 24.59 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 27.50.
What is the quality score of FLUI?
Fluicell AB has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fluicell AB (FLUI)?
Our calculated price target is the estimate of kr 24.59 (as of Nov 10, 2026). Cautious scenario kr 18.44, optimistic scenario kr 30.73. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Fluicell AB stock forecast for 2026?
Our estimate puts fair value at kr 24.59, about 11% lower versus a price of kr 27.50 (overvalued). Cautious scenario kr 18.44, optimistic scenario kr 30.73. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Fluicell AB (FLUI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fluicell AB it is kr 24.59 per share (as of Nov 10, 2026), against a price of kr 27.50.
Is Fluicell AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, FLUI trades above its calculated fair value: price kr 27.50, fair value kr 24.59, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FLUI?
No. The price is what the market pays today (kr 27.50); the fair value is what the company's own numbers justify (kr 24.59). For Fluicell AB the two are kr 2.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fluicell AB worth?
The market values Fluicell AB at about 37.8M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 27.50; our models calculate a fair value of kr 24.59 per share.
What do the bullish and bearish scenarios say about FLUI?
Our models span a range for Fluicell AB: cautious scenario kr 18.44, base kr 24.59, optimistic kr 30.73 per share (as of Nov 10, 2026, price kr 27.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FLUI?
Fluicell AB trades at a price-to-earnings ratio of 13.5 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 24.59 is built from several models across several years. Other multiples: P/B 3.5, P/S 2.0, EV/EBITDA 12.1.
How solid is the balance sheet of Fluicell AB (FLUI)?
Balance-sheet figures for Fluicell AB (as of Nov 10, 2026): return on equity 18.6%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is FLUI from its 52-week high?
Fluicell AB trades at kr 27.50, about 52% below its 52-week high of kr 57.20 and 246% above the low of kr 7.95 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 24.59 is for.
Which stocks are comparable to Fluicell AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fluicell AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 27.50, calculated fair value kr 24.59 (−11%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Fluicell AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fluicell AB (FLUI)?
The closing price on Nov 10, 2026 was kr 27.50. Our estimate is kr 24.59, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fluicell AB right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Fluicell AB

How large is the market capitalisation of Fluicell AB (FLUI)?
The market capitalisation of Fluicell AB is 37.8M SEK (≈ $3.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fluicell AB (FLUI)?
The price-to-sales ratio of Fluicell AB is 2.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fluicell AB (FLUI)?
Earnings per share at Fluicell AB are kr 2.04 (price ÷ EPS = P/E 13.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Fluicell AB (FLUI)?
The net margin of Fluicell AB is 15.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fluicell AB (FLUI)?
The return on equity (ROE) of Fluicell AB is 18.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fluicell AB (FLUI)?
On an EBIT basis the return on assets of Fluicell AB is −109% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fluicell AB (FLUI)?
The operating margin of Fluicell AB is 30.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fluicell AB (FLUI)?
Revenue at Fluicell AB is growing +934% versus a year earlier (3y avg +22.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Fluicell AB (FLUI) generate?
The free cash flow of Fluicell AB is −13.6M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Fluicell AB (FLUI) hold?
Fluicell AB holds more cash than debt, 2.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Fluicell AB in the live analysis

One click puts Fluicell AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.